Fibrosis-4指数可预测2075例慢性HBV感染患者的肝硬化风险与肝病相关死亡
该研究纳入2075例未治疗、无肝硬化的慢性HBV感染者(82.1%为HBeAg阴性),平均随访15.47年,发现基线FIB-4>1.29者较FIB-4<1.29者肝硬化、肝硬化相关并发症及肝病相关死亡风险均显著升高(HR分别为6.19、6.88、7.79),FIB-4<1.29对预测最低疾病进展风险有用。
要点
- 在无肝硬化的慢性HBV感染者中,基线FIB-4>1.29与肝硬化风险升高相关(HR 6.19)。
- FIB-4>1.29者肝硬化相关并发症风险升高(HR 6.88),肝病相关死亡风险升高(HR 7.79)。
- FIB-4<1.29可用于预测最低的疾病进展风险,即使HBeAg阴性低风险者也可分层。
核心结论
- 在无肝硬化的慢性HBV感染者中,较高的FIB-4指数与不良肝脏事件风险增加相关,FIB-4<1.29有助于预测最低的疾病进展风险。
研究设计与样本
- 纳入2075例未治疗、无肝硬化的慢性HBV感染者,其中82.1%为HBeAg阴性,探索基线FIB-4水平对肝硬化、肝硬化相关并发症及肝病相关死亡风险的 stratified 分析,平均随访15.47年。
主要发现
- 平均随访15.47年期间,基线FIB-4>1.29者较FIB-4<1.29者肝硬化风险升高(HR 6.19, 95%CI 4.76-8.05)。
- FIB-4>1.29者较FIB-4<1.29者肝硬化相关并发症风险升高(HR 6.88, 95%CI 3.68-12.86),肝病相关死亡风险升高(HR 7.79, 95%CI 4.54-13.37)。
- 随访前3年内FIB-4保持稳定,其动力学与不良肝脏事件发生持续相关。
- FIB-4指数1.29甚至可在HBeAg阴性且疾病进展低风险(HBV DNA<2000 IU/mL、HBsAg<1000 IU/mL且ALT<40 U/L)的患者中分层所有不良肝脏事件风险。
- 在15年随访期间,FIB-4<1.29者中仅1例发生肝硬化,未发生其他事件。
关键数值与推荐
- FIB-4>1.29 vs FIB-4<1.29:肝硬化HR 6.19(95%CI 4.76-8.05),肝硬化相关并发症HR 6.88(95%CI 3.68-12.86),肝病相关死亡HR 7.79(95%CI 4.54-13.37)。
临床怎么用
- 在无肝硬化的慢性HBV感染者中,可依据基线FIB-4指数进行风险分层,FIB-4<1.29提示疾病进展风险最低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrosis-4 index (FIB-4) is a surrogate marker for hepatic fibrosis in hepatitis B virus (HBV) carriers. AIM: To investigate whether FIB-4 index stratifies the risks of adverse liver events. METHODS: A total of 2075 treatment-naïve, noncirrhotic the patients with chronic HBV infection were included. Most of them (82.1%) were HBeAg-negative patients and their baseline FIB-4 levels were explored to stratify the risks of cirrhosis, cirrhosis-related complications and liver-related mortality. RESULTS: During a mean follow-up period of 15.47 years, we found a higher baseline FIB-4 index was associated with increased incidence rates of cirrhosis in addition to the common host and viral factors. Patients with FIB-4 >1.29, compared to those with FIB-4 <1.29, were associated with increased risks of cirrhosis, cirrhosis-related complications and liver-related mortality with the hazard ratio (95% confidence interval) of 6.19 (4.76-8.05), 6.88, (3.68-12.86) and 7.79, (4.54-13.37) respectively. Within the first 3 years of follow-up, FIB-4 remained stable and its kinetics were consistently associated with the develoopment of adverse liver events. Furthermore, FIB-4 index of 1.29 was able to stratify all the risks of adverse liver events even in HBeAg-negative patients with a low risk of disease progression (HBV DNA <2000 IU/mL, HBsAg <1000 IU/mL and ALT <40 U/L). Only 1 patient with FIB-4 index <1.29 developed cirrhosis but not other events within 15 years of follow-up. CONCLUSIONS: In noncirrhotic patients with chronic HBV infection, a higher FIB-4 index was associated with increased risks of adverse liver events. FIB-4 index <1.29 is useful for the prediction of the lowest risks of disease progression.
引用
- Tseng TC, Liu CJ, Su TH, et al. Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. Aliment Pharmacol Ther. 2018. PMID: 29601647. doi:10.1111/apt.14619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。